Viewing data from:

APTIVUS

NDA

TIPRANAVIR | N021814 | BOEHRINGER INGELHEIM PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Aptivus (2023)

Total Spending

$1.3M

Total Claims

577

Beneficiaries

Avg Cost/Unit

$17.69

Spending Trend

$2.2M(2019)→$2.0M(2020)→$1.7M(2021)→$1.4M(2022)→$1.3M(2023)

YoY Change:+4.8%

5yr CAGR:+5.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain0 active DMFs2 inactive

0 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

CATALENT PHARMA SOLUTIONS LLCInactiveTIPRANAVIR CAPSULES 250 MG (IMPRINTED)

DMF 177832004

RP SCHERER GMBH AND CO KGInactiveTIPRANAVIR CAPSULES 250 MG (IMPRINT)

DMF 207072007

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

17 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#001 — 250MG

RLD

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jun 22, 2005

No patent or exclusivity listings for this strength.